GSA Capital Partners LLP Invests $798,000 in Madrigal Pharmaceuticals, Inc. $MDGL

GSA Capital Partners LLP purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,739 shares of the biopharmaceutical company’s stock, valued at approximately $798,000.

Several other institutional investors have also recently bought and sold shares of the business. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of Madrigal Pharmaceuticals by 361.6% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 18,363 shares of the biopharmaceutical company’s stock valued at $8,435,000 after buying an additional 14,385 shares during the last quarter. Assetmark Inc. lifted its position in Madrigal Pharmaceuticals by 3.3% in the 3rd quarter. Assetmark Inc. now owns 5,058 shares of the biopharmaceutical company’s stock valued at $2,320,000 after acquiring an additional 160 shares in the last quarter. Rhumbline Advisers boosted its stake in Madrigal Pharmaceuticals by 3.4% during the 3rd quarter. Rhumbline Advisers now owns 27,263 shares of the biopharmaceutical company’s stock valued at $12,504,000 after purchasing an additional 900 shares during the last quarter. Baader Bank Aktiengesellschaft bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $885,000. Finally, Bryce Point Capital LLC bought a new stake in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $536,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on MDGL shares. Citizens Jmp lifted their target price on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the company a “market outperform” rating in a research report on Tuesday, January 20th. Oppenheimer lifted their price objective on shares of Madrigal Pharmaceuticals from $600.00 to $650.00 and gave the stock an “outperform” rating in a report on Thursday, November 20th. Cantor Fitzgerald upgraded shares of Madrigal Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Tuesday, November 4th. UBS Group set a $900.00 price target on shares of Madrigal Pharmaceuticals in a research report on Friday, December 19th. Finally, B. Riley Financial boosted their price target on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $669.86.

Madrigal Pharmaceuticals Price Performance

Shares of NASDAQ:MDGL opened at $435.01 on Friday. The company has a market capitalization of $9.88 billion, a P/E ratio of -33.80, a price-to-earnings-growth ratio of 6.18 and a beta of -1.01. The company’s 50-day moving average is $521.61 and its 200 day moving average is $482.31. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.26 and a current ratio of 3.44. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). The company had revenue of $321.08 million for the quarter, compared to analysts’ expectations of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 42.55% and a negative net margin of 30.08%.The business’s quarterly revenue was up 210.8% on a year-over-year basis. During the same quarter last year, the business posted ($2.71) EPS. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

Insider Buying and Selling at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, CEO William John Sibold sold 2,400 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $575.34, for a total transaction of $1,380,816.00. Following the completion of the transaction, the chief executive officer owned 150,074 shares in the company, valued at $86,343,575.16. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Mardi Dier sold 4,173 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $578.34, for a total transaction of $2,413,412.82. Following the completion of the sale, the chief financial officer directly owned 10,440 shares in the company, valued at approximately $6,037,869.60. This trade represents a 28.56% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 99,537 shares of company stock valued at $53,485,702 in the last quarter. Insiders own 21.50% of the company’s stock.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.